The international iReceptor Plus consortium, an international project co-funded by the EU and the Canadian government, is launching the technology tools and infrastructure developed within the EU-funded project, to facilitate the sharing and analyses of antibody and T-cell receptor sequencing (AIRR-seq) data from COVID-19 patients as soon as these data become available, it was reported on Monday.
Presently, the iReceptor Plus project is building a technological platform with accompanying bioinformatics and machine learning tools to facilitate sharing and joint research of specific immunological data for the purpose of basic research and developing new therapeutics and vaccines for infectious diseases, autoimmune diseases and cancer. Among others, the iReceptor Plus Platform is at the stage where it is ready to incorporate data and be utilised by its industrial partner, 10x Genomics.
The iReceptor Plus project works in close coordination with the Adaptive Immune Receptor Repertoire (AIRR) Community. In collaboration with the AIRR Community, iReceptor Plus is mapping the different efforts in producing AIRR-seq data in the context of COVID-19. The aim is to approach the companies and research groups that are producing the data and offer full support in making it publicly available. Rapid sharing of these data across laboratories and institutions through the AIRR Data Commons, accessible through the iReceptor Gateway, is critical to the search for anti-COVID-19 therapeutics and vaccines.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients